Table 3.
ALK inhibitors in clinical use and development
| Drug | Phase | Tumors | Common toxicities | Reference |
|---|---|---|---|---|
| Crizotinib | III | NSCLC | Visual disturbance, nausea, vomiting, constipation, edema | [68-71] |
| Alectinib | II/III | NSCLC, ALCL, neuroblastoma | Neutropenia, elevated CPK | [79-82] |
| Ceritinib | II/III | NSCLC | Diarrhea, elevated transaminases | [86-91] |
| AP-26113 | I/II | NSCLC | Nausea, fatigue, diarrhea | [92-94] |
| ASP-3026 | IB | NSCLC | Nausea, vomiting, constipation, abdominal pain | [95,96] |
| X-376 | Preclinical | NSCLC, ALCL, neuroblastoma cell lines | N/A | [98] |
| X-396 | Preclinical | NSCLC, ALCL, neuroblastoma cell lines | N/A | [98] |
| TSR-011 | I/II | NSCLC, pancreatic, ovarian, and salivary gland cancers | Dysaesthesia, QTc prolongation | [99] |
| CEP-37440 | I | NSCLC, SCCHN, colorectal, pancreatic, prostate, and breast cancers | Nausea, vomiting, diarrhea headaches | [100] |
| NMS-E628 | I/II | advanced solid tumors | N/A | [102] |
| PF-06463922 | I/IIA | NSCLC | N/A | [103] |
ALCL-anaplastic large cell lymphoma; CPK-creatine phosphokinase; N/A-not available; NSCLC-non-small cell lung cancer; SCCHN-squamous cell cancer of head and neck.